(RNA) Avidity Biosciences - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 212m USD | Total Return: -47.3% in 12m

RNA Therapeutics, Drug Development, Muscular Dystrophy, Cardiomyopathy
Total Rating 23
Safety 38
Buy Signal -0.92
Biotechnology
Industry Rotation: -3.7
Market Cap: 212M
Avg Turnover: 4.82M USD
ATR: 8.01%
Peers RS (IBD): 0.1
Risk 5d forecast
Volatility154%
Rel. Tail Risk-35.5%
Reward TTM
Sharpe Ratio0.30
Alpha-120.25
Character TTM
Beta2.012
Beta Downside1.073
Drawdowns 3y
Max DD83.11%
CAGR/Max DD-0.06
EPS (Earnings per Share) EPS (Earnings per Share) of RNA over the last years for every Quarter: "2021-03": -0.64, "2021-06": -0.7, "2021-09": -0.68, "2021-12": -0.82, "2022-03": -0.71, "2022-06": -0.92, "2022-09": -0.82, "2022-12": -0.88, "2023-03": -0.74, "2023-06": -0.66, "2023-09": -0.71, "2023-12": -0.79, "2024-03": -0.79, "2024-06": -0.65, "2024-09": -0.65, "2024-12": -0.8, "2025-03": -0.9, "2025-06": -1.21, "2025-09": -1.27, "2025-12": -1.59, "2026-03": 0,
EPS CAGR: 23.81%
EPS Trend: -3.4%
Last SUE: 4.00
Qual. Beats: 1
Revenue Revenue of RNA over the last years for every Quarter: 2021-03: 2.704, 2021-06: 2.607, 2021-09: 2.163, 2021-12: 1.852, 2022-03: 1.795, 2022-06: 2.178, 2022-09: 2.482, 2022-12: 2.769, 2023-03: 2.233, 2023-06: 2.316, 2023-09: 2.818, 2023-12: 2.193, 2024-03: 3.543, 2024-06: 2.045, 2024-09: 2.336, 2024-12: 2.973, 2025-03: 1.573, 2025-06: 3.847, 2025-09: 12.475, 2025-12: 0.859, 2026-03: null,
Rev. CAGR: -17.84%
Rev. Trend: 16.5%
Last SUE: 0.06
Qual. Beats: 0

Warnings

Altman Z'' -15.00 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: RNA Avidity Biosciences

Avidity Biosciences, Inc. (RNA) is a biopharmaceutical company specializing in RNA therapeutics delivered via antibody oligonucleotide conjugates (AOCs). This approach merges monoclonal antibody specificity with RNA therapeutic precision to address previously untreatable diseases. The biotechnology sector is characterized by high research and development costs and long development cycles.

The companys clinical pipeline includes three programs: Delpacibart zotadirsen for Duchenne muscular dystrophy (Phase 2), Delpacibart etedesiran for myotonic dystrophy type 1 (Phase 3), and Delpacibart braxlosiran for facioscapulohumeral muscular dystrophy (Phase 1/2). Avidity Biosciences also develops precision cardiology candidates for rare genetic cardiomyopathies. Biopharmaceutical companies typically generate revenue through product sales post-approval or through licensing agreements.

For more detailed financial and operational analysis, further research on platforms like ValueRay is recommended.

Headlines to Watch Out For
  • Myotonic dystrophy drug trial results impact stock
  • Duchenne muscular dystrophy program progress drives valuation
  • New AOC platform targets expand market potential
  • Regulatory approvals for pipeline drugs are critical
Piotroski VR‑10 (Strict) 0.0
Net Income: -495.6m TTM > 0 and > 6% of Revenue
FCF/TA: -1.84 > 0.02 and ΔFCF/TA -164.2 > 1.0
NWC/Revenue: 1.23k% < 20% (prev 13.3k%; Δ -12.0k% < -1%)
CFO/TA -1.80 > 3% & CFO -499.9m > Net Income -495.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.53 > 1.5 & < 3
Outstanding Shares: last quarter (137.7m) vs 12m ago 7.17% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 2.04% > 50% (prev 0.70%; Δ 1.34% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.83 (Total Current Assets 272.8m - Total Current Liabilities 41.8m) / Total Assets 278.4m
B: -5.67 (Retained Earnings -1.58b / Total Assets 278.4m)
C: -0.57 (EBIT TTM -525.1m / Avg Total Assets 921.1m)
D: -22.16 (Book Value of Equity -1.58b / Total Liabilities 71.1m)
Altman-Z'' Score: -40.14 = D
Beneish M -3.70
DSRI: 0.26 (Receivables 12.4m/28.2m, Revenue 18.8m/10.9m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.0 (AQ_t 0.0 / AQ_t-1 0.00)
SGI: 1.72 (Revenue 18.8m / 10.9m)
TATA: 0.02 (NI -495.6m - CFO -499.9m) / TA 278.4m)
Beneish M-Score: -3.70 (Cap -4..+1) = AAA
What is the price of RNA shares? As of April 12, 2026, the stock is trading at USD 12.71 with a total of 1,028,056 shares traded.
Over the past week, the price has changed by -7.02%, over one month by -13.36%, over three months by -82.43% and over the past year by -47.28%.
Is RNA a buy, sell or hold? Avidity Biosciences has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy RNA.
  • StrongBuy: 9
  • Buy: 6
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the RNA price?
Analysts Target Price 25 96.7%
Avidity Biosciences (RNA) - Fundamental Data Overview as of 08 April 2026
P/S = 11.3916
P/B = 1.0067
Revenue TTM = 18.8m USD
EBIT TTM = -525.1m USD
EBITDA TTM = -522.4m USD
Long Term Debt = 3.67m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.67m USD (from shortTermDebt, last quarter)
Debt = 3.67m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -266.3m USD (from netDebt column, last quarter)
Enterprise Value = 212.1m USD (floored to Market Cap, CCE > MCap+Debt)
 Interest Coverage Ratio = unknown (Ebit TTM -525.1m / Interest Expense TTM 0.0)
 EV/FCF = -0.41x (Enterprise Value 212.1m / FCF TTM -511.8m)
 FCF Yield = -241.3% (FCF TTM -511.8m / Enterprise Value 212.1m)
 FCF Margin = -2.73k% (FCF TTM -511.8m / Revenue TTM 18.8m)
 Net Margin = -2.64k% (Net Income TTM -495.6m / Revenue TTM 18.8m)
 Gross Margin = unknown ((Revenue TTM 18.8m - Cost of Revenue TTM 139.6m) / Revenue TTM)
 Tobins Q-Ratio = 0.76 (Enterprise Value 212.1m / Total Assets 278.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 3.67m)
Taxrate = 21.0% (US default 21%)
NOPAT = -414.9m (EBIT -525.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.53 (Total Current Assets 272.8m / Total Current Liabilities 41.8m)
Debt / Equity = 0.02 (Debt 3.67m / totalStockholderEquity, last quarter 207.3m)
 Debt / EBITDA = 0.51 (negative EBITDA) (Net Debt -266.3m / EBITDA -522.4m)
 Debt / FCF = 0.52 (negative FCF - burning cash) (Net Debt -266.3m / FCF TTM -511.8m)
 Total Stockholder Equity = 735.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.80% (Net Income -495.6m / Total Assets 278.4m)
RoE = -67.39% (Net Income TTM -495.6m / Total Stockholder Equity 735.4m)
RoCE = -71.06% (EBIT -525.1m / Capital Employed (Equity 735.4m + L.T.Debt 3.67m))
 RoIC = -35.96% (negative operating profit) (NOPAT -414.9m / Invested Capital 1.15b)
 WACC = 12.84% (E(212.1m)/V(215.8m) * Re(13.06%) + D(3.67m)/V(215.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 34.56%
 [DCF] Fair Price = unknown (Cash Flow -511.8m)
 EPS Correlation: -3.37 | EPS CAGR: 23.81% | SUE: 4.0 | # QB: 1
Revenue Correlation: 16.51 | Revenue CAGR: -17.84% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.01 | Chg7d=-1.010 | Chg30d=-1.010 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=-4.14 | Chg7d=-4.140 | Chg30d=-4.140 | Revisions Net=+0 | Growth EPS=+8.0% | Growth Revenue=-57.0%
EPS next Year (2027-12-31): EPS=-4.62 | Chg7d=-4.620 | Chg30d=-4.620 | Revisions Net=+0 | Growth EPS=-11.6% | Growth Revenue=+0.0%
External Resources
Dataroma Stockcircle